Filing Flows › Editas Medicine (EDIT) › Q3 2026 › vs Q2 2026
Editas Medicine (EDIT) Q3 2026 vs Q2 2026 (quarter over quarter)
Editas Medicine's revenue fell $1.5M (-13%) from $11.9M in Q2 2026 to $10.4M in Q3 2026.
Editas Medicine, Q3 2026: revenue $10.4M (+37% year over year), operating margin -234.3%, net loss $23.4M, operating cash flow −$21.2M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $10.4M | $11.9M | −$1.5M | -13% |
| Other income, net | $889K | $324K | $565K | +174% |
| Net loss | $23.4M | $18.2M | $5.2M | +28% |
| Costs & expenses | $34.6M | $30.4M | $4.2M | +14% |
| Operating costs | $34.6M | $30.4M | $4.2M | +14% |
| Operating cash sources | $24.1M | $32.2M | −$8.0M | -25% |
| Depreciation | $385K | $416K | −$31K | -7% |
| Share-based compensation | $2.6M | $2.2M | $378K | +17% |
| Cash used in operations | $21.2M | $29.6M | −$8.4M | -28% |
| Net loss absorbed | $23.4M | $18.2M | $5.2M | +28% |
| Working capital & other | $753K | $13.9M | −$13.2M | -95% |
Questions
How much did Editas Medicine's revenue grow quarter over quarter in Q3 2026?
Editas Medicine's revenue fell $1.5M (-13%) from $11.9M in Q2 2026 to $10.4M in Q3 2026.